摘要
目的探讨阿瑞匹坦联合盐酸格拉司琼注射液和地塞米松预防乳腺癌FAC方案化疗致恶心、呕吐的治疗效果。方法收集中国医科大学附属盛京医院2014年1月—2014年6月行FAC方案化疗乳腺癌患者76例,按照入院先后顺序采用随机分组分为观察组(阿瑞匹坦+盐酸格拉司琼注射液+地塞米松)及对照组(盐酸格拉司琼注射液+地塞米松),每组各38例,比较2组对预防化疗所致恶心、哎吐的临床疗效,不良反应及对生活质量的影响。结果观察组恶心控制率为84.2%,优于对照组的65.7%(x^2=4.324,P<0.05);观察组急性呕吐有效率为81.6%,优于对照组的63.2%(x^2=4.213,P<0.05);观察组延迟性呕吐有效率为79.0%,优于对照组的60.6%(x^2=3.172,P<0.05)。不良反应方面,2组比较无显著性差异(P>0.05);生存质量评价,观察组明显高于对照组,2组比较差异有统计学意义(P<0.05)。结论阿瑞匹坦联合盐酸格拉司琼注射液、地塞米松能够有效预防乳腺癌FAC方案化疗所致恶心呕吐,不良反应轻,提高患者生存质量,值得推广。
Objective To investigate the effect of aprepitanl combined granisetron hydrochloride injection and dexamethasone in the prevention of nausea,vomiting induced by FAC regimen chemotherapy of breast cancer.Methods From 2014 January to 2014 June,collected 76 cases of breast cancer patients who were received chemotherapy of FAC regimen in Shengjing Hospital Affiliated to China Medical University,in accordance with the order of admission,they were randomly divided into observation group(aprepitanl + granisetron hydrochloride injection + dexamethasone) and control group(granisetron hydrochloride injection + dexamethasone).each group of 38 cases,compared the 2 groups' clinical efficacy of prevention of nausea,vomiting induced by chemotherapy,adverse reactions and the quality of life.Results The observation group nausea control rate was 84.2%,which was belter than the control group of 65.7%(χ^2 =4.324,P〈0.05);observation groups acute vomiting efficiency was 81.6%,which was better than the control group of 63.2%(χ^2 =4.213,P〈0.05);the effective rate of delayed vomiting in the observation group was 79.0%,which was better than the control group of 60.6%(χ^2 =3.172,P〈0.05).Adverse reactions revealed no significant differences between the 2 groups(P〉0.05);evaluation of the quality of life,the observation group was significantly higher than that in the control group,there was significant difference between the 2 groups(P〈0.05).Conclusion Aprepitanl combined granisetron hydrochloride injection and dexamethasone can effectively prevent nausea and vomiting caused by FAC chemotherapy in breast cancer patients with mild adverse reactions,it can improve the quality of life of patients and worthy of promotion.
出处
《疑难病杂志》
CAS
2015年第1期45-48,共4页
Chinese Journal of Difficult and Complicated Cases
关键词
阿瑞匹坦
乳腺癌
FAC方案
化疗
止吐剂
Aprepitant
Breast cancer
FAC regimen
Chemotherapy
Antiemetic agent